As shown in Fig 1B, patients whose cancers demonstrated EMAST (presumed hMSH3-deficient) had improved survival with adjuvant 5-FU therapy (P = 0.034) to the same extent as patients whose cancers did not demonstrate EMAST (MMR-proficient) (P = 0.043) (Fig 1C). This evidence concerns the gene MSH3 and cancer.